Posted by: Salvatore J. Zambri, founding partner
Dow Jones Newswires (12/8, Dooren) reported that Thomas Laughren, the director of FDA’s division of psychiatric products, said Tuesday that the agency is weighing tougher warning labels for antipsychotics that might cause weight gain and diabetes. According to the report, “the agency has asked manufacturers of drugs like Seroquel, Abilify and Zyprexa for all of the information they have on metabolic side effects such as increases in blood glucose” to determine whether warnings need to be improved. This comes in the wake of concerns of how antipsychotic medication has been effecting children in particular.
Like all drugs, antipsychotic medication should never be taken without a doctor’s prescription, and a physician should never prescribe this medication unless it is in the best interest of the patient and only after the patient has been fully informed of all of the risks and benefits of the drug.
About the author:
Mr. Zambri is Past-President of the Trial Lawyers Association of Metropolitan Washington, DC and has been rated by Washingtonian magazine as a “Big Gun” and among the “top 1%” of all lawyers in the Washington metropolitan area. The magazine also describes him as “one of Washington’s best–most honest and effective lawyers” whose practice is dedicated to handling catastrophic personal injury matters, including medical malpractice actions stemming from defective or dangerous medications and medical errors. He has also been named a “DC Super Lawyer” by Super Lawyer magazine (March/April 2009)–a national publication that honors the top lawyers in America.
Mr. Zambri is regularly asked to present seminars to lawyers and doctors, as well as both medical and law students concerning medication errors, medical malpractice litigation, and safety improvements.
If you want more information about your legal rights, please email Mr. Zambri at firstname.lastname@example.org or call him at 202-822-1899.